Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.

Deneau MR, Mack C, Abdou R, Amin M, Amir A, Auth M, Bazerbachi F, Marie Broderick A, Chan A, DiGuglielmo M, El-Matary W, El-Youssef M, Ferrari F, Furuya KN, Gottrand F, Gupta N, Homan M, Jensen MK, Kamath BM, Mo Kim K, Kolho KL, Konidari A, Koot B, Iorio R, Martinez M, Mohan P, Palle S, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Valentino PL, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Miloh T.

Hepatol Commun. 2018 Sep 25;2(11):1369-1378. doi: 10.1002/hep4.1251. eCollection 2018 Nov.

2.

Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.

Liu T, Yang H, Fan W, Tu J, Li TWH, Wang J, Shen H, Yang J, Xiong T, Steggerda J, Liu Z, Noureddin M, Maldonado SS, Annamalai A, Seki E, Mato JM, Lu SC.

Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5.

PMID:
29733835
3.

[Primary sclerosing cholangitis : Current diagnostics and treatment].

Liwinski T, Schramm C.

Internist (Berl). 2018 Jun;59(6):551-559. doi: 10.1007/s00108-018-0428-z. Review. German.

PMID:
29700559
4.

Caroli's Disease as a Cause of Chronic Epigastric Abdominal Pain: Two Case Reports and a Brief Review of the Literature.

Cabral Correia P, Morgado B.

Cureus. 2017 Sep 20;9(9):e1701. doi: 10.7759/cureus.1701. Review.

5.

Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.

Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, Thorburn D.

Cochrane Database Syst Rev. 2017 Mar 28;3:CD011343. doi: 10.1002/14651858.CD011343.pub2. [Epub ahead of print] Review.

6.

Advances in primary sclerosing cholangitis.

Horsley-Silva JL, Carey EJ, Lindor KD.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):68-77. doi: 10.1016/S2468-1253(16)30010-3. Epub 2016 Aug 10. Review.

PMID:
28404115
7.

Emerging treatments for primary sclerosing cholangitis.

Rodriguez EA, Carey EJ, Lindor KD.

Expert Rev Gastroenterol Hepatol. 2017 May;11(5):451-459. doi: 10.1080/17474124.2017.1293524. Epub 2017 Feb 22. Review.

PMID:
28276816
8.

[A contribution to the differential diagnostics of sclerosing cholangitides].

Blaho M, Dítě P, Bojková M, Rydlo M, Kupka T, Svoboda P, Klvaňa P, Martínek A.

Vnitr Lek. Winter 2017;63(1):50-55. Czech.

PMID:
28225291
9.

Risk and Surveillance of Cancers in Primary Biliary Tract Disease.

Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M, Imam M.

Gastroenterol Res Pract. 2016;2016:3432640. doi: 10.1155/2016/3432640. Epub 2016 Jun 19. Review.

10.

Child with Jaundice and Pruritus: How to Evaluate?

Jagadisan B, Srivastava A.

Indian J Pediatr. 2016 Nov;83(11):1311-1320. Epub 2016 Mar 2. Review.

PMID:
26932879
11.

Controversies in the management of primary sclerosing cholangitis.

Nayagam JS, Pereira SP, Devlin J, Harrison PM, Joshi D.

World J Hepatol. 2016 Feb 18;8(5):265-72. doi: 10.4254/wjh.v8.i5.265. Review.

12.

 Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.

Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH.

Ann Hepatol. 2016 Mar-Apr;15(2):246-53. doi: 10.5604/16652681.1193721.

PMID:
26845602
13.

A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Goode EC, Rushbrook SM.

Ther Adv Chronic Dis. 2016 Jan;7(1):68-85. doi: 10.1177/2040622315605821. Review.

14.

Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT).

Lozano E, Monte MJ, Briz O, Hernández-Hernández A, Banales JM, Marin JJ, Macias RI.

J Control Release. 2015 Oct 28;216:93-102. doi: 10.1016/j.jconrel.2015.08.022. Epub 2015 Aug 14.

PMID:
26278512
15.

Primary sclerosing cholangitis: a clinical update.

Williamson KD, Chapman RW.

Br Med Bull. 2015 Jun;114(1):53-64. doi: 10.1093/bmb/ldv019. Epub 2015 May 16. Review.

PMID:
25981516
16.

Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian national association for study of the liver.

Dhiman RK, Saraswat VA, Valla DC, Chawla Y, Behera A, Varma V, Agarwal S, Duseja A, Puri P, Kalra N, Rameshbabu CS, Bhatia V, Sharma M, Kumar M, Gupta S, Taneja S, Kaman L, Zargar SA, Nundy S, Singh SP, Acharya SK, Dilawari JB.

J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S2-S14. doi: 10.1016/j.jceh.2014.02.003. Epub 2014 Feb 25. Review.

17.

Primary sclerosing cholangitis.

Williamson KD, Chapman RW.

Dig Dis. 2014;32(4):438-45. doi: 10.1159/000358150. Epub 2014 Jun 23. Review.

PMID:
24969292
18.

Diagnosis and classification of primary sclerosing cholangitis.

Yimam KK, Bowlus CL.

Autoimmun Rev. 2014 Apr-May;13(4-5):445-50. doi: 10.1016/j.autrev.2014.01.040. Epub 2014 Jan 11. Review.

PMID:
24424180
19.

Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.

Karlsen TH, Vesterhus M, Boberg KM.

Aliment Pharmacol Ther. 2014 Feb;39(3):282-301. doi: 10.1111/apt.12581. Epub 2013 Dec 29. Review.

20.

Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells.

Lee HM, Jeong YI, Kim DH, Kwak TW, Chung CW, Kim CH, Kang DH.

Int J Pharm. 2013 Sep 15;454(1):74-81. doi: 10.1016/j.ijpharm.2013.06.035. Epub 2013 Jul 6.

PMID:
23834828

Supplemental Content

Loading ...
Support Center